BR9815289A - Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid - Google Patents

Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid

Info

Publication number
BR9815289A
BR9815289A BR9815289-0A BR9815289A BR9815289A BR 9815289 A BR9815289 A BR 9815289A BR 9815289 A BR9815289 A BR 9815289A BR 9815289 A BR9815289 A BR 9815289A
Authority
BR
Brazil
Prior art keywords
infectious disease
antigen
cancer
disease agent
agent
Prior art date
Application number
BR9815289-0A
Other languages
Portuguese (pt)
Inventor
Ronald M Burch
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR9815289A publication Critical patent/BR9815289A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"IMUNOGLOBULINA MODIFICADA, MOLéCULA, áCIDONUCLEICO ISOLADO, CéLULA CONTENDO O MESMO, ANIMALNãO-HUMANO RECOMBINANTE, COMPOSIçãOFARMACêUTICA, COMPOSIçãO DE VACINA, PROCESSOSPARA IDENTIFICAR OU MEDIR OU DETECTAR UM ANTìGENODE CANCER, UM ANTIGENO DE UM AGENTE DE DOENçAINFECCIOSA, UM LIGANTE, E UM RECEPTOR EM UMAAMOSTRA A SER TESTADA, KITS PARA DETECçãO DE UMANTìGENO DE CâNCER, DE UM ANTìGENO DE UM AGENTEDE DOENçA INFECCIOSA, DE UM RECEPTOR CELULAR PARAUM AGENTE DE DOENçA INFECCIOSA, DE UM LIGANTE, E DEUM ANTìGENO DE CâNCER, PROCESSOS DE DIAGNóSTICOOU DE EXAME PARA A PRESENçA DE OU UMAPREDISPOSIçãO PARA DESENVOLVIMENTO DE UM CâNCERTIPIFICADO PELA PRESENçA AUMENTADA DE UMANTìGENO DE CâNCER, E PARA A PRESENçA DE UMAGENTE DE DOENçA INFECCIOSA, PROCESSOS DETRATAMENTO OU DE PREVENçãO DE UM CâNCERTIPIFICADO PELA PRESENçA DE UM ANTìGENO DE CâNCER,DE UMA DOENçA INFECCIOSA TIPIFICADA PELA PRESENçADE UM ANTìGENO DE AGENTE DE DOENçA INFECCIOSA, EDE UMA DOENçA CAUSADA POR UM AGENTE DE DOENçAINFECCIOSA QUE SE LIGA EM UM RECEPTOR CELULAR,PROCESSO PARA MODULAçãO DE ATIVIDADE DE UMPRIMEIRO MEMBRO DE UM PAR DE LIGAçãO, PROCESSO DEPRODUçãO DE UMA IMUNOGLOBULINA MODIFICADA,PROCESSO DE PRODUçãO DE UM áCIDO NUCLEICOCODIFICADOR DE IMUNOGLOBULINA MODIFICADA, E, áCIDONUCLEICO ISOLADO". A invenção proporciona moléculas deimunoglobulina modificada, particularmente anticorpos, queimunoespecificamente ligam um membro de um par de ligaçãocujas imunoglobulinas possuem um domínio variável contendo umaou mais regiões de determinação complementar que contêm asequência de amino-ácidos de um sítio de ligação para aquelemembro do par de ligação, cujo sítio é derivado do outro membrodo par de ligação e não é naturalmente verificado na região dedeterminação complementar. A invenção proporcionaadicionalmente uso da imunoglobulina modificada em terapia e emdiagnóstico."MODIFIED IMMUNOGLOBULIN, MOLECULE, ISOLATED ACIDONUCLEIC, CELL CONTAINING THE SAME, RECOMBINANT ANIMALHUMAN, PHARMACEUTICAL COMPOSITION, VACCINE COMPOSITION, PROCESSING TO IDENTIFY AN AGENT, DETECTING AN AGENT, DETECTING AN AGENT, DETECTING AN AGENT A SAMPLE TO BE TESTED, KITS FOR THE DETECTION OF A CANCER UMANTIGEN, AN ANTIGEN OF AN INFECTIOUS DISEASE AGENT, A CELL RECEPTOR FOR AN INFECTIOUS DISEASE AGENT, A BINDER, AND AN ANTIGENOUS OF CHARACTERISTICS OF OR AN APARTMENT FOR THE DEVELOPMENT OF A CANCER CERTIFIED BY THE INCREASED PRESENCE OF A CANCER UMANTIGEN, AND FOR THE PRESENCE OF AN INFECTIOUS DISEASE AGENT, PROCESSES OF PREVENTING OR PREVENTING A CANCER OF AN AGAINST AGAIN INFECTIOUS DISEASE AGENT ANTIGEN, EDE A DISEASE CAUSED BY AN INFECTIOUS DISEASE AGENT CONNECTING TO A CELLULAR RECEIVER, PROCESS FOR MODULATING THE ACTIVITY OF A FIRST MEMBER OF A CONNECTION PAIR, PROCESS OF DEPRODUCING A MODIFIED IMMUNE GLOBAL BODY, UNAUTHORGANIZED, UNHAPPY, UNHAPPY, UNHAPPY, UNHAPPY, UNHAPPY. ". The invention provides modified immunoglobulin molecules, particularly antibodies, that immunospecifically bind a member of a binding pair whose immunoglobulins have a variable domain containing one or more complementary determination regions that contain the amino acid sequence of a binding site for that member of the binding pair, whose site is derived from the other member of the binding pair and is not naturally found in the complementary determination region. The invention further provides for the use of the modified immunoglobulin in therapy and diagnosis.

BR9815289-0A 1997-11-14 1998-11-13 Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid BR9815289A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US8140398P 1998-04-10 1998-04-10
PCT/US1998/024302 WO1999025378A1 (en) 1997-11-14 1998-11-13 Immunoglobulin molecules having a synthetic variable region and modified specificity

Publications (1)

Publication Number Publication Date
BR9815289A true BR9815289A (en) 2001-12-26

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9815580-6A BR9815580A (en) 1997-11-14 1998-11-13 Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule
BR9815289-0A BR9815289A (en) 1997-11-14 1998-11-13 Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9815580-6A BR9815580A (en) 1997-11-14 1998-11-13 Vaccine composition, processes to generate an anti-idiotype response in a subject, to treat or prevent cancer, to treat or prevent an infectious disease, to prepare a first immunoglobulin molecule, and, first immunoglobulin molecule

Country Status (9)

Country Link
EP (2) EP1030684A4 (en)
JP (2) JP2002507544A (en)
KR (2) KR20010015818A (en)
CN (2) CN1327388A (en)
AU (2) AU763029B2 (en)
BR (2) BR9815580A (en)
CA (2) CA2309990A1 (en)
IL (2) IL136113A0 (en)
WO (2) WO1999025379A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029443A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
DK1092779T3 (en) * 1999-10-11 2010-02-15 Pasteur Institut Lentivirus virus vectors for the preparation of immunotherapeutic preparations
WO2001088159A2 (en) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Cd28 synthebody for the modulation of immune responses
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE320450T1 (en) 2000-12-05 2006-04-15 Alexion Pharma Inc RATIONALLY DESIGNED ANTIBODIES
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
ATE554787T1 (en) * 2002-04-09 2012-05-15 Univ Missouri TREATMENT OF TYPE 1 DIABETES BEFORE AND AFTER EXPRESSION OF PREDIPOSITION MARKERS
JP4563171B2 (en) 2002-05-24 2010-10-13 シェーリング コーポレイション Neutralizing human anti-IGFR antibody
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
JP2008521907A (en) 2004-12-03 2008-06-26 シェーリング コーポレイション Biomarkers for preselecting patients for anti-IGF1R treatment
UA99714C2 (en) * 2006-08-28 2012-09-25 Ля Хойя Інстітьют Фор Еллерджи Енд Іммьюнолоджи Monoclonal antibody that specifically binds to light
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CN101970500B (en) * 2008-03-12 2013-08-14 伊姆克罗尼责任有限公司 Anti-tyrp1 antibodies
WO2010126972A1 (en) * 2009-04-29 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Erg monoclonal antibodies
CN102816240B (en) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 Fusion protein and fusion protein expression vector thereof
CA2837472A1 (en) 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
WO2013076580A2 (en) * 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
JP5437525B1 (en) 2012-12-28 2014-03-12 株式会社ナード研究所 Tyrosine derivative and method for producing tyrosine derivative
CN105705522B (en) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 Epitope vaccine aiming at low-immunogenicity protein and preparation method and application thereof
CN103275914B (en) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 Bacterial ghost presenting protective antigens and application thereof
CN105263953B (en) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 Porcine parvovirus 5A, methods of use, and vaccines
RU2695375C2 (en) * 2014-05-19 2019-07-23 Вало Терапьютикс Ой Coated oncolytic adenovirus for anticancer vaccines
CN105693859B (en) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 Anti-human G2A monoclonal antibody and the kit for detecting human macrophage G2A expression quantity
CN111978382B (en) * 2020-09-03 2022-03-04 吉林大学第一医院 Preparation method and application of recombinant protein of Sporothrix globosum Gp70
CN112646029B (en) * 2020-12-30 2022-07-29 深圳清华大学研究院 Antibody of mature brain-derived neurotrophic factor, application thereof and diagnostic kit
CN115856296B (en) * 2022-12-16 2023-07-25 华北理工大学 Monoclonal antibody for resisting shigella and application thereof in detection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP0460076B1 (en) * 1989-02-24 1995-11-29 The Regents Of The University Of California Genetically engineered immunoglobulins
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Also Published As

Publication number Publication date
EP1030684A1 (en) 2000-08-30
WO1999025379A1 (en) 1999-05-27
BR9815580A (en) 2002-01-29
IL136113A0 (en) 2001-05-20
CA2310269A1 (en) 1999-05-27
EP1032420A1 (en) 2000-09-06
AU737457B2 (en) 2001-08-23
AU763029B2 (en) 2003-07-10
AU1459899A (en) 1999-06-07
CN1327388A (en) 2001-12-19
WO1999025378A1 (en) 1999-05-27
KR20010015818A (en) 2001-02-26
EP1032420A4 (en) 2004-09-15
AU2003252902A1 (en) 2003-11-06
IL136114A0 (en) 2001-05-20
JP2001526021A (en) 2001-12-18
WO1999025378A9 (en) 1999-08-12
CA2309990A1 (en) 1999-05-27
KR20010015817A (en) 2001-02-26
CN1294517A (en) 2001-05-09
JP2002507544A (en) 2002-03-12
EP1030684A4 (en) 2004-09-15
AU1459799A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
BR9815289A (en) Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid
Grey et al. Human monoclonal γG-cryoglobulins with anti—γ-globulin activity
Landry et al. Systemic lupus erythematosus. Studies of the antibodies bound to skin
Brown et al. Activation of antibody Fc function by antigen-induced conformational changes.
Lamelin et al. MOUSE THYMUS-INDEPENDENT AND THYMUS-DERIVED LYMPHOID CELLS: I. Immunofluorescent and Functional Studies
Akizuki et al. Purification of an acidic nuclear protein antigen and demonstration of its antibodies in subsets of patients with sicca syndrome
KR910005862A (en) New hydrophilic derivatives, diagnostic or therapeutic kits and immunoreagents containing them for diagnosis or treatment
ES512498A0 (en) "METHOD AND ITS CORRESPONDING DEVICE FOR THE TESTING OF ANTIBODIES WITH RESPECT TO SOLUBLE ANTIGENS".
CA1197777A (en) Coated cells and their use
Mukojima et al. Circulating antigen-antibody complex associated with Epstein-Barr virus in recurrent Burkitt's lymphoma
JP2592121B2 (en) Methods and kits for the diagnosis of IgA kidney disease
Shu et al. Nuclear deposits of immunoglobulins in skin of patients with systemic lupus erythematosus.
Iwatsuki et al. Comparative studies on naturally occurring antikeratin antibodies in human sera
Walters et al. Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis.
JPH06502912A (en) Analyte variant analysis
Singh et al. Detection of circulating immune complexes by a C1q-microplate ELISA system
Loos The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages
Abelev a-Fetoprotein production by normal liver and liver tumors
Rushmore et al. Purification and characterization of P-52 (glutathione S-transferase-P or 7-7) from normal liver and putative preneoplastic liver nodules
Bluestone et al. Detection and characterization of DNA in mixed (IgG-IgM) cryoglobulins
Stetler et al. Anti-RNA polymerase I antibodies: potential role in the induction and progression of murine lupus nephritis.
ATE420365T1 (en) PREPARATION OF SPHERES FOR DIAGNOSTIC TESTS
Gupta et al. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography
Stewart et al. The influence of enzymatic cleavage and chemical modification of human and rabbit IgG on their reactivity with staphylococcal protein A.
JPS63150669A (en) Method of measuring hyaluronic acid

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.